PortfoliosLab logo
Amphastar Pharmaceuticals, Inc. (AMPH)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US03209R1032

CUSIP

03209R103

IPO Date

Jun 25, 2014

Highlights

Market Cap

$1.16B

EPS (TTM)

$3.06

PE Ratio

8.01

PEG Ratio

2.77

Total Revenue (TTM)

$558.19M

Gross Profit (TTM)

$280.64M

EBITDA (TTM)

$203.23M

Year Range

$22.64 - $53.96

Target Price

$38.00

Short %

12.29%

Short Ratio

4.24

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Amphastar Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%200.00%300.00%400.00%500.00%December2025FebruaryMarchAprilMay
181.71%
189.05%
AMPH (Amphastar Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Amphastar Pharmaceuticals, Inc. (AMPH) returned -33.61% year-to-date (YTD) and -41.60% over the past 12 months. Over the past 10 years, AMPH returned 5.38% annually, underperforming the S&P 500 benchmark at 10.43%.


AMPH

YTD

-33.61%

1M

3.79%

6M

-46.52%

1Y

-41.60%

5Y*

5.60%

10Y*

5.38%

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of AMPH, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-6.09%-18.47%1.97%-15.80%0.98%-33.61%
2024-13.73%-12.72%-5.71%-6.06%2.62%-5.50%8.80%11.99%-0.43%4.12%-10.57%-17.84%-39.97%
20237.99%5.29%17.70%-4.61%24.04%29.52%5.60%-12.16%-13.73%-1.57%24.41%9.82%120.74%
2022-0.86%20.01%29.56%-1.20%4.71%-6.33%7.47%-20.83%-5.07%9.96%-4.56%-4.98%20.31%
2021-9.60%-3.58%4.51%-5.02%8.74%6.55%3.92%-6.16%-3.31%-1.74%4.71%19.07%15.81%
2020-1.97%-18.61%-3.57%14.22%9.97%20.49%-10.86%1.80%-8.00%4.48%-9.34%13.23%4.25%
201914.37%9.18%-17.79%5.68%-10.84%9.66%-4.55%11.46%-11.71%-2.60%1.01%-1.13%-3.07%
2018-3.12%-1.50%2.12%1.81%-17.23%-3.42%14.35%8.77%1.37%-6.70%21.00%-8.38%3.43%
2017-14.50%-1.78%-6.27%4.14%13.05%4.63%-3.25%-7.35%11.62%1.12%8.41%-1.79%4.45%
2016-15.32%-12.61%13.96%2.50%27.89%2.48%0.37%17.43%-0.16%-4.38%11.74%-9.13%29.44%
20154.48%15.42%6.86%-3.34%6.09%14.60%-7.51%-20.85%-9.17%1.28%29.65%-7.30%22.57%
201414.40%-11.29%36.15%-3.64%-12.96%2.86%11.31%32.69%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AMPH is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AMPH is 77
Overall Rank
The Sharpe Ratio Rank of AMPH is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of AMPH is 55
Sortino Ratio Rank
The Omega Ratio Rank of AMPH is 77
Omega Ratio Rank
The Calmar Ratio Rank of AMPH is 1212
Calmar Ratio Rank
The Martin Ratio Rank of AMPH is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Amphastar Pharmaceuticals, Inc. (AMPH) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Amphastar Pharmaceuticals, Inc. Sharpe ratio is -1.06. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Amphastar Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-1.06
0.48
AMPH (Amphastar Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Amphastar Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-62.08%
-7.82%
AMPH (Amphastar Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Amphastar Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amphastar Pharmaceuticals, Inc. was 64.63%, occurring on Apr 16, 2025. The portfolio has not yet recovered.

The current Amphastar Pharmaceuticals, Inc. drawdown is 62.08%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-64.63%Aug 9, 2023424Apr 16, 2025
-49.92%Mar 4, 2019266Mar 20, 2020456Jan 10, 2022722
-43.39%Nov 18, 201678Mar 14, 2017420Nov 9, 2018498
-42.11%Jun 26, 2015170Feb 29, 2016115Aug 11, 2016285
-35.49%Apr 14, 2022144Nov 8, 2022109Apr 18, 2023253

Volatility

Volatility Chart

The current Amphastar Pharmaceuticals, Inc. volatility is 13.65%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%December2025FebruaryMarchAprilMay
13.65%
11.21%
AMPH (Amphastar Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Amphastar Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Amphastar Pharmaceuticals, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -2.0%.


0.000.200.400.600.801.001.20AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
0.92
0.94
Actual
Estimate

Valuation

The Valuation section provides an overview of how Amphastar Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for AMPH, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/E ratio of 8.0. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for AMPH compared to other companies in the Drug Manufacturers - Specialty & Generic industry. AMPH currently has a PEG ratio of 2.8. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AMPH relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/S ratio of 1.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AMPH in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items